Blood biomarker for multiple sclerosis
- Yavor Yalachkov
- Feb 28
- 1 min read
Today, I would like to draw your attention to a recent publication by a highly promising clinician scientist, Dr. Kimberly Körbel, a valued member of my lab.
🎓 A collaborative effort within ECTRIMS
As part of the ECTRIMS Winter School 2024 study group, Kim co-authored an important meta-regression analysis examining treatment effects on serum/plasma neurofilament light chain (NfL) and their association with clinical and radiological endpoints in randomized controlled trials (RCTs).
The analysis includes data from more than 6,000 patients — a remarkable collaborative effort.
📊 Why this work matters
This study is particularly important because it synthesizes data across numerous trials, substantially strengthening the evidence for NfL as a surrogate marker of disease activity in Multiple Sclerosis (MS).
Importantly, the analysis also provides a more nuanced perspective on clinical versus radiological endpoints, emphasizing that different outcome measures reflect different underlying mechanisms and pathophysiological processes in MS.
🧠 In other words: for the right measurement, you need the right tool.
👏 Hats off to Kim and the entire ECTRIMS Winter School 2024 study group for this excellent work!
📖 Read the publication here: